The company announced in an exchange filing that the EIR pertains to an inspection conducted by the USFDA at its Oncology Formulation Facility (F-2), which includes both injectable and oral solid formulations. The inspection was carried out from 7 October 2024 to 8 October 2024.
In an earlier filing dated 9th October 2024, the company informed that it had successfully completed the USFDA inspection for its Oncology Formulation Facility (F-2) located at Panelav. The inspection was successfully completed without any Form 483 observation.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company that has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.
The company’s consolidated net profit tumbled 23.29% to Rs 138.42 crore in Q3 FY25, compared with Rs 180.45 crore posted in Q3 FY24. Revenue from operations was at Rs 1,692.74 crore in the third quarter of FY25, up 3.81% year on year (YoY).